Phan-Kiet Tran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Phan-Kiet Tran has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Vinit Parida
Entrepreneurship and Innovation Luleå University of Technology Luleå Sweden
2 shared publications - Annika Rydberg
Department of Clinical Sciences, Pediatrics, Umea University , Umea
1 shared publication - Arun Thirumalesh Madanaguli
Area of Marketing and Strategy Indian Institute of Management Rohtak Rohtak India
1 shared publication - Constance Gesina Weismann
Department of Clinical Sciences Lund, Lund University, Sweden
1 shared publication - Edin Omerbasic
Pediatric Cardiac Surgery, Children's Heart Center, Skåne University Hospital, Lund, Sweden
1 shared publication Gunnar Sjöberg
Department of Women's and Children's Health Karolinska Institute Stockholm Sweden
1 shared publication
Latest Publications
- 9 November 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Engineering Management
- Vol. 71 (00189391) , 13006-13019
Technological Innovation Adoption Among Swedish Healthcare Professionals: A Contingency Technology Adoption Framework
Technological innovation adoption by healthcare professionals directly impacts enhanced patient care and overall community well-being. However, the perspective of healthcare professionals in evaluating and adopting these technological innovations should be addressed. Drawing on innovation adoption and resistance theories, in this article, we aim to capture their perceptions of the barriers they face and the adoption behaviors they express through a technology adoption contingency framework. The qualitative investigation on Swedish healthcare professionals shows that healthcare innovations are multistakeholder systems where the healthcare-professional's perception of multiple individual, organizational, and administrative barriers causes hesitancy in adopting technologies. However, hesitancy does not always lead to complete resistance; sometimes, it can lead to partial or complete adoption of the technology, contingent on the severity of the barriers and their interrelationship. The findings, summarized in a contingency framework for evaluating barriers to adoption and hesitancy behaviors, highlight the importance of individual perceptions in the adoption and success of complex healthcare innovations. They show why empowering adopters to choose how and when to use the innovation can be a powerful tool in reducing hesitancy.
- 9 November 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Engineering Management
- Vol. 71 (00189391) , 13006-13019
Technological Innovation Adoption Among Swedish Healthcare Professionals: A Contingency Technology Adoption Framework
Technological innovation adoption by healthcare professionals directly impacts enhanced patient care and overall community well-being. However, the perspective of healthcare professionals in evaluating and adopting these technological innovations should be addressed. Drawing on innovation adoption and resistance theories, in this article, we aim to capture their perceptions of the barriers they face and the adoption behaviors they express through a technology adoption contingency framework. The qualitative investigation on Swedish healthcare professionals shows that healthcare innovations are multistakeholder systems where the healthcare-professional's perception of multiple individual, organizational, and administrative barriers causes hesitancy in adopting technologies. However, hesitancy does not always lead to complete resistance; sometimes, it can lead to partial or complete adoption of the technology, contingent on the severity of the barriers and their interrelationship. The findings, summarized in a contingency framework for evaluating barriers to adoption and hesitancy behaviors, highlight the importance of individual perceptions in the adoption and success of complex healthcare innovations. They show why empowering adopters to choose how and when to use the innovation can be a powerful tool in reducing hesitancy.
- Open Access
- 24 September 2022
- Published by Elsevier in Journal of Innovation & Knowledge
- Vol. 7 (4)
Perceived risk and the need for trust as drivers of improved surgical skills in 3D surgical video technology
- 24 September 2022
- Published by Elsevier in Journal of Innovation & Knowledge
- Vol. 7 (4)
Open AccessPerceived risk and the need for trust as drivers of improved surgical skills in 3D surgical video technology
- Open Access
- 5 April 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (7) , e022929
Impact of Left Ventricular Morphology on Adverse Outcomes Following Stage 1 Palliation for Hypoplastic Left Heart Syndrome: 20 Years of National Data From Sweden
Background: Hypoplastic left heart syndrome is associated with significant morbidity and mortality. We aimed to assess the influence of left ventricular morphology and choice of shunt on adverse outcome in patients with hypoplastic left heart syndrome and stage 1 palliation. Methods and Results: This was a retrospective analysis of patients with hypoplastic left heart syndrome with stage 1 palliation between 1999 and 2018 in Sweden. Patients (n=167) were grouped based on the anatomic subtypes aortic‐mitral atresia, aortic atresia‐mitral stenosis (AA‐MS), and aortic‐mitral stenosis. The left ventricular phenotypes including globular left ventricle (Glob‐LV), miniaturized and slit‐like left ventricle (LV), and the incidence of major adverse events (MAEs) including mortality were assessed. The overall mortality and MAEs were 31% and 41%, respectively. AA‐MS (35%) was associated with both mortality (all other subtypes versus AA‐MS: interstage‐I: hazard ratio [HR], 2.7; P =0.006; overall: HR, 2.2; P =0.005) and MAEs (HR, 2.4; P =0.0009). Glob‐LV (57%), noticed in all patients with AA‐MS, 61% of patients with aortic stenosis‐mitral stenosis, and 19% of patients with aortic atresia‐mitral atresia, was associated with both mortality (all other left ventricular phenotypes versus Glob‐LV: interstage‐I: HR, 4.5; P =0.004; overall: HR, 3.4; P =0.0007) and MAEs (HR, 2.7; P =0.0007). There was no difference in mortality and MAEs between patients with AA‐MS and without AA‐MS with Glob‐LV ( P >0.15). Patients with AA‐MS (35%) or Glob‐LV (38%) palliated with a Blalock‐Taussig shunt had higher overall mortality compared with those palliated with Sano shunts, irrespective of the stage 1 palliation year (AA‐MS: HR, 2.6; P =0.04; Glob‐ LV: HR, 2.1; P =0.03). Conclusions: Glob‐LV and AA‐MS are independent morphological risk factors for adverse short‐ and long‐ term outcome, especially if a Blalock‐Taussig shunt is used as part of stage 1 palliation. These findings are important for the clinical management of patients with hypoplastic left heart syndrome.
- 5 April 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (7) , e022929
Open AccessImpact of Left Ventricular Morphology on Adverse Outcomes Following Stage 1 Palliation for Hypoplastic Left Heart Syndrome: 20 Years of National Data From Sweden
Background: Hypoplastic left heart syndrome is associated with significant morbidity and mortality. We aimed to assess the influence of left ventricular morphology and choice of shunt on adverse outcome in patients with hypoplastic left heart syndrome and stage 1 palliation. Methods and Results: This was a retrospective analysis of patients with hypoplastic left heart syndrome with stage 1 palliation between 1999 and 2018 in Sweden. Patients (n=167) were grouped based on the anatomic subtypes aortic‐mitral atresia, aortic atresia‐mitral stenosis (AA‐MS), and aortic‐mitral stenosis. The left ventricular phenotypes including globular left ventricle (Glob‐LV), miniaturized and slit‐like left ventricle (LV), and the incidence of major adverse events (MAEs) including mortality were assessed. The overall mortality and MAEs were 31% and 41%, respectively. AA‐MS (35%) was associated with both mortality (all other subtypes versus AA‐MS: interstage‐I: hazard ratio [HR], 2.7; P =0.006; overall: HR, 2.2; P =0.005) and MAEs (HR, 2.4; P =0.0009). Glob‐LV (57%), noticed in all patients with AA‐MS, 61% of patients with aortic stenosis‐mitral stenosis, and 19% of patients with aortic atresia‐mitral atresia, was associated with both mortality (all other left ventricular phenotypes versus Glob‐LV: interstage‐I: HR, 4.5; P =0.004; overall: HR, 3.4; P =0.0007) and MAEs (HR, 2.7; P =0.0007). There was no difference in mortality and MAEs between patients with AA‐MS and without AA‐MS with Glob‐LV ( P >0.15). Patients with AA‐MS (35%) or Glob‐LV (38%) palliated with a Blalock‐Taussig shunt had higher overall mortality compared with those palliated with Sano shunts, irrespective of the stage 1 palliation year (AA‐MS: HR, 2.6; P =0.04; Glob‐ LV: HR, 2.1; P =0.03). Conclusions: Glob‐LV and AA‐MS are independent morphological risk factors for adverse short‐ and long‐ term outcome, especially if a Blalock‐Taussig shunt is used as part of stage 1 palliation. These findings are important for the clinical management of patients with hypoplastic left heart syndrome.
- Open Access
- 1 March 2022
- Published by Elsevier in Journal of Surgical Research
- Vol. 271, 106-116
Vision-Based Tracking of Surgical Motion During Live Open-Heart Surgery
- 1 March 2022
- Published by Elsevier in Journal of Surgical Research
- Vol. 271, 106-116
Open AccessVision-Based Tracking of Surgical Motion During Live Open-Heart Surgery